Literature DB >> 19650763

Biochemical consequences of sedlin mutations that cause spondyloepiphyseal dysplasia tarda.

Mei Y Choi1, Caleb C Y Chan, Danny Chan, Keith D K Luk, Kathryn S E Cheah, Julian A Tanner.   

Abstract

SEDT (spondyloepiphyseal dysplasia tarda) is a late-onset X-linked recessive skeletal dysplasia caused by mutations in the gene SEDL coding for sedlin. In the present paper, we investigated four missense mutations observed in SEDT and compare biochemical and cellular characteristics relative to the wild-type protein to address the mechanism of disease and to gain insight into the function of the sedlin protein. In situ hybridization and immunohistochemical experiments in mouse growth plates revealed sedlin to be predominantly expressed in proliferating and hypertrophic chondrocytes. Cell culture studies showed that the wild-type protein localized predominantly in the vicinity of the nucleus and the Golgi, with further localization around the cytoplasm, whereas mutation resulted in mislocalization. The D47Y mutant was expressed similarly to the wild-type, but the S73L, F83S and V130D mutants showed particularly low levels of expression that were rescued in the presence of the proteasome inhibitor MG132 (benzyloxycarbonyl-leucylleucylleucinal). Furthermore, whereas the D47Y mutant folded similarly and had similar stability to the wild-type sedlin as shown by CD and fluorescence, the S73L, F83S and V130D mutants all misfolded during expression. Two independent assays showed that the D47Y mutation resulted in an increased affinity for the transport protein particle component Bet3 compared with the wild-type sedlin. Our results suggest that the sedlin mutations S73L, F83S and V130D cause SEDT by sedlin misfolding, whereas the D47Y mutation may influence normal TRAPP (transport protein particle) dynamics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650763     DOI: 10.1042/BJ20090541

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  9 in total

Review 1.  A trapper keeper for TRAPP, its structures and functions.

Authors:  Sidney Yu; Yongheng Liang
Journal:  Cell Mol Life Sci       Date:  2012-06-06       Impact factor: 9.261

2.  The TRAPP complex mediates secretion arrest induced by stress granule assembly.

Authors:  Francesca Zappa; Cathal Wilson; Giuseppe Di Tullio; Michele Santoro; Piero Pucci; Maria Monti; Davide D'Amico; Sandra Pisonero-Vaquero; Rossella De Cegli; Alessia Romano; Moin A Saleem; Elena Polishchuk; Mario Failli; Laura Giaquinto; Maria Antonietta De Matteis
Journal:  EMBO J       Date:  2019-08-20       Impact factor: 11.598

3.  Molecular architecture of the TRAPPII complex and implications for vesicle tethering.

Authors:  Calvin K Yip; Julia Berscheminski; Thomas Walz
Journal:  Nat Struct Mol Biol       Date:  2010-10-24       Impact factor: 15.369

4.  Trs20 is required for TRAPP II assembly.

Authors:  David Taussig; Zhanna Lipatova; Jane J Kim; Xuiqi Zhang; Nava Segev
Journal:  Traffic       Date:  2013-03-25       Impact factor: 6.215

5.  Biomedical and social aspects of spondyloepiphyseal dysplasia tarda cases from bengkulu district of indonesia.

Authors:  A Ruyani; B Karyadi; C Muslim
Journal:  Int J Biomed Sci       Date:  2012-12

6.  The adaptor function of TRAPPC2 in mammalian TRAPPs explains TRAPPC2-associated SEDT and TRAPPC9-associated congenital intellectual disability.

Authors:  Min Zong; Xing-gang Wu; Cecilia W L Chan; Mei Y Choi; Hsiao Chang Chan; Julian A Tanner; Sidney Yu
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

7.  A novel deletion variant in TRAPPC2 causes spondyloepiphyseal dysplasia tarda in a five-generation Chinese family.

Authors:  Cai Zhang; Caiqi Du; Juan Ye; Feng Ye; Renfa Wang; Xiaoping Luo; Yan Liang
Journal:  BMC Med Genet       Date:  2020-05-29       Impact factor: 2.103

8.  A novel missense variant in TRAPPC2 causes X-linked spondyloepiphyseal dysplasia tarda: A case report.

Authors:  Li Zhang; Jinling Wang; Guanping Dong; Dingwen Wu; Wei Wu
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

9.  New therapeutic targets in rare genetic skeletal diseases.

Authors:  Michael D Briggs; Peter A Bell; Michael J Wright; Katarzyna A Pirog
Journal:  Expert Opin Orphan Drugs       Date:  2015-09-24       Impact factor: 0.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.